Oral formulations are set to dominate headlines in 2026, offering convenience and eliminating cold-chain requirements - attributes that could make long-term obesity care more practical and unlock the maintenance opportunity
The log 2 -transformed gProcessed signals of the three biological replicates are shown
Plas ma AUC of sitagliptin increased in a dose-proportional manner
An additional Phase II study, CT388-104, is evaluating the efficacy, safety, and tolerability of enicepatide in participants who are living with obesity or are overweight and have T2D
Dysmenorrhea, painful intercourse, painful bowel movements, bloating (often called "endo belly"), fatigue, and depression and anxiety are all part of the picture
Taken together, results of this meta-analysis are able to provide preliminary evidence in favor of GLP-1-based therapies in overcoming atherosclerosis development/progression which is also substantiated by the significant decreases in the total cholesterol, LDL-cholesterol and triglycerides observed in the studies which fulfilled inclusion criteria of this study
